Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China

NCT ID: NCT05125341

Last Updated: 2022-07-05

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 67 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-11-25
• Study Completion Date: 2022-04-30

Brief Summary

This is a single-center observational study conducted in adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis.

This observational study consists of two parts, one part is retrospective study which aims to collect medical chart data to calculate the mean change or mean incidence rates of LDH, hemoglobin, PNH-related symptoms and PNH-related events over 6 months.

The other part is cross-sectional study to detect the total C5 level in PUMCH at the latest follow-up visit in eligible PNH patients with high-risk hemolysis, to show the difference between eligible PNH patients and healthy people and to explore the related clinical factor influencing high-level total C5 using logistic regression model.

Conditions

Paroxysmal Nocturnal Hemoglobinuria, Natural History Study

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: OTHER

Eligibility Criteria

Inclusion Criteria

1. Meet the diagnostic criteria for paroxysmal nocturnal hemoglobinuria;

2. Age ≥ 18 years old;

3. PNH clone size of granulocytes or monocytes (CD59 or Flaer) ≥ 10%;

4. LDH≥1.5 ULN;

5. Accompanied by at least one PNH-related symptoms: fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia symptoms, major adverse vascular events (including thrombosis), dysphagia, erectile dysfunction;

6. Transfusion-dependent PNH patients;

7. There are at least 6 months consecutive data of diagnosis and treatment after the data collection time point;

8. Patients agreed to participate in the study by signing informed consent or giving oral informed consent.

Exclusion Criteria

1. Patients are under the treatment of the C1/C3/C5 complement inhibitors currently or in the past;

2. Patients have received bone marrow transplantation;

3. platelet count <30*10 9/L or absolute neutrophil count <0.5*10 9/L;

4. Patients have clinically significant heart, liver, or lung diseases, or have related medical history.

5. Patients have comorbidities of rheumatoid disease, HIV infection, active HBV infection, HCV infection and other diseases that affect the body's immune function;

6. Severe missing data in the records of diagnosis and treatment after the data collection time point;

7. Other patients who are not suitable to participate in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CARE Pharma Shanghai Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bing Han, MD

Role: PRINCIPAL_INVESTIGATOR

Peking Union Medical College Hospital

Locations

Peking Union Medical College Hospital

Beijing, , China

Countries

China

Other Identifiers

CAN106-01001

Identifier Type: -

Identifier Source: org_study_id